Table 1.
Baseline patients characteristics
| Characteristic | N (%) |
|---|---|
| Age | |
| < 75 years | 319 (82.0) |
| ≥ 75 years | 70 (18.0) |
| Median (range) age, years 65 (34–85) | |
| Gender | |
| Male | 291 (74.8) |
| Female | 98 (25.2) |
| ECOG performance status | |
| 0 | 176 (47.1) |
| 1 | 174 (46.5) |
| 2 | 24 (6.4) |
| NA | 15 |
| IMDC prognostic group | |
| Favourable | 62 (20.2) |
| Intermediate | 212 (69.1) |
| Poor | 33 (10.7) |
| NA | 82 |
| Nephrectomy | |
| Yes | 369 (94.9) |
| No | 20 (5.1) |
| Histology | |
| Clear-cell | 356 (91.5) |
| Non-clear-cell | 26 (6.7) |
| Undifferentiated/Unknown | 7 (1.8) |
| Metastasis site | |
| Lung | 286 (73.5) |
| Lymph node | 238 (69.2) |
| Bone | 193 (49.6) |
| Liver | 128 (32.9) |
| Brain | 32 (8.2) |
| Number of prior systemic therapies | |
| 1 | 80 (20.7) |
| 2 | 137 (35.4) |
| ≥ 3 | 170 (43.9) |
| First-line therapy | |
| Sunitinib | 261 (67.4) |
| Pazopanib | 80 (20.7) |
| Other | 46 (11.9) |
| Prior everolimus | |
| Yes | 163 (42.1) |
| No | 224 (57.9) |
Abbreviations: N number, NA not assessed, ECOG Eastern Cooperative Oncology Group, IMDC International Metastatic Renal Cell Carcinoma Database Consortium